This week in aesthetics, we highlight the launch of Nutrafol Postpartum, the creation of the AACS Women in Cosmetic Surgery forum, and more.
This week in aesthetics, experts examine the use of trichoscopy for hair and scalp disease diagnosis, Revance provides an update on the approval process for DAXI, Nutrafol launches a new postpartum nutraceutical, The Cutaneous Connection Podcast dives into how health care policy impacts gender and sexual minority patients, Hugel America announces the BLA application FDA approval for letibotulinumtoxinA, and AACS announces the creation of the Women in Cosmetic Surgery forum.
Trichoscopy, which is based on dermoscopy, can be a valuable tool for diagnosing conditions that cause hair loss and inflammatory scalp disease.
Revance provides an update on the approval process for its injectable daxibotulinumtoxinA (DAXI) for the treatment of glabellar lines.
Nutrafol launches a new nutraceutical, called Postpartum, aimed at helping women’s hair health post-pregnancy.
We dive into how health care policy impacts gender and sexual minority patients, including exploring the Affordable Care Act (ACA) and Medicaid expansion, and identifying state and federal nondiscrimination protections that help defend equal access to health care for this patient population.
Hugel America announces the BLA application FDA approval for letibotulinumtoxinA as a treatment for glabellar lines in adult patients.
The American Academy of Cosmetic Surgery announced the creation of a new forum, WICS, focused on the growth and development of female cosmetic surgeon members.